Compass Therapeutics (NASDAQ:CMPX – Get Free Report) posted its earnings results on Thursday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), FiscalAI reports.
Compass Therapeutics Stock Performance
Shares of NASDAQ CMPX traded up $0.16 during midday trading on Friday, hitting $2.15. 3,825,555 shares of the stock traded hands, compared to its average volume of 2,660,902. Compass Therapeutics has a one year low of $1.61 and a one year high of $6.88. The firm has a market capitalization of $387.19 million, a P/E ratio of -5.37 and a beta of 0.92. The firm has a 50-day moving average of $2.09 and a two-hundred day moving average of $3.86.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of CMPX. Russell Investments Group Ltd. increased its position in shares of Compass Therapeutics by 48.5% during the 4th quarter. Russell Investments Group Ltd. now owns 11,558 shares of the company’s stock valued at $62,000 after purchasing an additional 3,773 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Compass Therapeutics in the fourth quarter worth approximately $71,000. Xponance LLC bought a new stake in Compass Therapeutics during the fourth quarter valued at approximately $55,000. Focus Partners Wealth grew its position in Compass Therapeutics by 16.2% during the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock valued at $56,000 after buying an additional 2,206 shares during the period. Finally, BNP Paribas Financial Markets grew its position in Compass Therapeutics by 105.8% during the third quarter. BNP Paribas Financial Markets now owns 19,523 shares of the company’s stock valued at $68,000 after buying an additional 10,038 shares during the period. Institutional investors own 68.43% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on CMPX
Key Stories Impacting Compass Therapeutics
Here are the key news stories impacting Compass Therapeutics this week:
- Positive Sentiment: Piper Sandler raised its price target on Compass Therapeutics from $4 to $6 and upgraded its outlook to “overweight,” implying substantial potential upside from recent trading levels. Benzinga article
- Positive Sentiment: HC Wainwright maintained its “Buy” rating and $24 price target, signaling significant long-term upside if the company’s development programs progress successfully. The firm also modestly improved its FY2028 EPS forecast to a loss of $0.56 per share from a loss of $0.58.
- Neutral Sentiment: Analyst opinion is highly divided: Wall Street Zen reportedly downgraded Compass Therapeutics to “Strong Sell,” contrasting sharply with the Buy and Overweight ratings from HC Wainwright and Piper Sandler. Compass Therapeutics rating article
- Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q3 2026 to a loss of $0.15 from $0.11, Q4 2026 to a loss of $0.17 from $0.12, and full-year 2026 to a loss of $0.55 from $0.45. Its FY2027 forecast also declined slightly to a loss of $0.56 from $0.55.
About Compass Therapeutics
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.
Read More
- Five stocks we like better than Compass Therapeutics
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
